TransMedics Group, Inc.
TMDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.27 | 0.92 | 0.08 | 1.42 |
| FCF Yield | 1.62% | 1.82% | -1.32% | 0.29% |
| EV / EBITDA | 116.29 | 100.52 | 68.29 | 140.16 |
| Quality | ||||
| ROIC | 2.81% | 4.22% | 3.37% | 1.14% |
| Gross Margin | 58.80% | 61.38% | 61.47% | 59.21% |
| Cash Conversion Ratio | 2.86 | 2.62 | -0.11 | 2.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.46% | 52.07% | 60.03% | 67.80% |
| Free Cash Flow Growth | -24.94% | 376.10% | -593.53% | 114.65% |
| Safety | ||||
| Net Debt / EBITDA | 1.59 | 2.55 | 5.74 | 11.18 |
| Interest Coverage | 6.67 | 10.52 | 7.93 | 2.42 |
| Efficiency | ||||
| Inventory Turnover | 1.33 | 1.56 | 1.27 | 1.07 |
| Cash Conversion Cycle | 99.63 | 103.39 | 142.40 | 138.10 |